What is Alexandria Real Estate Q1 2026? Alexandria Real Estate Equities (NYSE: ARE) is the largest life science REIT in the United States, and on April 28, 2026, the company reported Q1 2026 results that crystallized a difficult truth for life science CRE investors: occupancy fell 320 basis points to 87.7%, public biotech leasing was zero for the quarter, and management cut full year occupancy guidance to 87%. Net income per share landed at $2.10, helped by a $366.4 million debt extinguishment gain, while FFO per share, as adjusted, came in at $1.73 on $671 million of revenue. For context on how AI is reshaping every corner of commercial real estate from wet labs to hyperscale data centers, see our pillar guide on AI commercial real estate.
Key Takeaways
- Alexandria reported 87.7% occupancy in Q1 2026, down 320 basis points, and cut year end occupancy guidance to 87% on continued weak biotech leasing demand.
- Q1 2026 revenue of $671 million missed the $684 million forecast, while adjusted FFO per share of $1.73 highlighted the gap between GAAP net income and operating cash flow.
- Public biotech leasing was zero in Q1 2026, with NIH and FDA leadership uncertainty extending what management called a very tough slog for publicly traded biotech tenants.
- Alexandria outlined a $2.9 billion 2026 disposition and partial interest sales plan, with $2.18 billion already identified, and projects annual construction spending to drop by roughly $500 million starting in 2027.
- Despite the headwinds, Alexandria captured roughly 2x its market share of leasing in Greater Boston, the San Francisco Bay Area, and San Diego in Q1 2026.
Alexandria Real Estate Q1 2026 Results in Plain Numbers
Alexandria Real Estate Equities reported Q1 2026 net income of $398.4 million, or $2.10 per diluted share, a sharp swing from a $0.07 loss per share in the year ago quarter. The headline beat was driven almost entirely by a $366.4 million gain on debt extinguishment, not by operations. Revenue of $671 million fell short of the $684.24 million consensus, and shares dropped roughly 11.6% in after hours trading on April 28, 2026 to about $44.90.
The metric most CRE investors should track here is FFO per share, as adjusted, which Alexandria pegged at $1.73 in Q1 2026. That is down from prior quarters and reflects the operating reality of a 320 basis point decline in occupancy, soft same property cash NOI growth, and 657,000 square feet of known lease expirations rolling to vacant in a single quarter. Total Q1 2026 leasing of 647,356 square feet was nearly half of the 1.2 million square feet leased in Q4 2025, and roughly 72% of that activity came from existing tenants rather than new logos.
For background on how Q1 2026 earnings season is playing out across CRE platforms, see our breakdown of CBRE's 81% Q1 2026 profit surge and First American's Q1 2026 data center title growth.
Why Public Biotech Leasing Hit Zero
The most striking data point in the print was that Alexandria recorded zero public biotech leasing in Q1 2026. Management framed this as a function of three overlapping forces:
- Capital markets selectivity: Public biotech IPO and follow on volumes remain depressed, restricting tenant ability to commit to long term lab leases.
- NIH and FDA leadership uncertainty: Regulatory and grant timing volatility has pushed many publicly traded biotechs to delay expansion decisions.
- 2027 expiration overhang: Alexandria flagged 1.5 million square feet of 2027 expirations and roughly $97 million of annual rental revenue at risk of downtime.
According to CBRE Research, the broader U.S. life science sector entered 2026 with elevated lab vacancy in Cambridge, South San Francisco, and San Diego after a wave of speculative deliveries from 2022 through 2024. Alexandria's private and pre IPO tenants continue to lease, but at a pace that does not yet offset the public biotech freeze.
The AI Angle: Lab Demand Is Bifurcating
Life science CRE in 2026 is splitting into two demand curves. On one side is traditional wet lab demand from public biotechs, which is contracting. On the other side is AI driven life science demand from companies running large protein folding, drug discovery, and computational biology workloads, which is growing.
That second curve is showing up in adjacent transactions across the AI Consulting Network coverage universe. OpenAI's GPT Rosalind life science model, the Novo Nordisk OpenAI partnership, and Eli Lilly's LillyPod AI supercomputer are all signals that the customer for next generation lab space increasingly looks like a computational biology team that needs a hybrid of bench space, secure compute, and high density power. The 33.9% AI in real estate CAGR toward a $1.3 trillion market by 2030 is being driven in part by exactly this category of tenant.
For Alexandria specifically, the question for CRE investors is whether the company can reposition select assets, especially the non income producing pipeline, toward AI native life science tenants and adjacent compute heavy workloads before the 2027 expiration wave hits. Management's $2.9 billion disposition plan and the planned $500 million reduction in annual construction spending suggest a deliberate retreat from speculative wet lab development and a focus on core, AI ready submarkets.
What CRE Investors Should Do Now
Three practical takeaways for CRE investors with life science exposure or interest:
- Reprice life science cap rates with realistic occupancy: Underwriting Boston, San Francisco, and San Diego lab assets at pre 2024 occupancy assumptions overstates NOI. Use 87% as the new base case and build in 1.5 million square feet of 2027 expiration risk for portfolios with public biotech tenancy.
- Watch the 2027 expiration cliff: Alexandria's $97 million of at risk rental revenue is the canary. Any life science REIT or fund with a similar 2027 maturity wall should be stressed for two scenarios: 12 month downtime versus 24 month downtime per expiring suite.
- Pivot diligence toward AI native tenant demand: Computational biology teams have very different infrastructure requirements than traditional wet lab tenants, including 200 to 400 watts per square foot of IT load, redundant fiber, and proximity to GPU rich data centers. Underwriting these tenants requires a different capex stack than legacy lab repositioning.
For personalized guidance on stress testing a life science portfolio against the AI driven demand pivot, connect with The AI Consulting Network. CRE investors looking for hands on AI implementation support across underwriting, lease abstraction, and tenant credit analysis can reach out to Avi Hacker, J.D. at The AI Consulting Network.
Frequently Asked Questions
Q: What were Alexandria Real Estate's Q1 2026 occupancy numbers?
A: Alexandria Real Estate reported 87.7% occupancy at the end of Q1 2026, down 320 basis points from the prior quarter. The decline was driven primarily by 657,000 square feet of known lease expirations going vacant. Year end 2026 occupancy guidance was cut from 88.5% to 87%.
Q: Why did Alexandria report zero public biotech leasing in Q1 2026?
A: Management cited capital markets selectivity, NIH and FDA leadership uncertainty, and weak public biotech equity issuance as the primary causes. Public biotech tenants are delaying expansion and renewal decisions, which produced no signed public biotech leases in the quarter.
Q: How is AI changing demand for life science real estate?
A: AI is creating a new tenant category, computational biology teams using large language models, protein folding tools, and AI drug discovery platforms, that requires a hybrid of wet lab space and high density compute. This is partially offsetting the contraction in traditional public biotech leasing and is one reason the AI in real estate market is forecast to reach $1.3 trillion by 2030 at a 33.9% CAGR.
Q: What is Alexandria's $2.9 billion disposition plan?
A: Alexandria outlined a $2.9 billion 2026 disposition and partial interest sales plan, with $2.18 billion already identified and in process as of the April 28, 2026 earnings call. The plan is designed to reduce non income producing assets from 17% of gross assets to 11% to 16% by year end 2026.
Q: Should life science CRE investors avoid the sector after Q1 2026?
A: Not necessarily, but underwriting needs to reset. Investors should use 87% as the new base case occupancy, stress test for the 2027 expiration cliff, and prioritize assets that can be repositioned for AI native life science tenants. The AI Consulting Network specializes in exactly this kind of repositioning analysis.